Oncolytics Biotech Inc.

Good morning and welcome to Oncolytics Biotech's fourth quarter and full year 2024 conference call. All participants are in a listen-only mode. There will be a question and answer session at the end of the call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Jan Patton, Director of Investor Relations and Communication. Please go ahead.

Thank you, Operator. Good morning, everyone, and welcome to Oncolitic's fourth quarter and full year 2024 earnings call. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Pella ReRep, including statements regarding the company's mission, strategy, and milestones, the company's belief as to the potential and mechanism of action of Pella ReRep as a cancer therapeutic, our search for a new permanent CEO, our potential registrational opportunities for Pella ReRap and our plans and strategies related thereto, the potential market for Pella ReRap and breast cancer, our plans to continue enrollment in Goblet Cohort 5, our ongoing business development initiatives, and other statements related to anticipated developments in the company's business. These statements are based on management current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties, and other factors not under the company's control and may cause actual results, performance, or achievements of the company to be materially different from the results, performance, or expectations implied by these forward-looking statements. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith, and our beliefs have a reasonable basis, but there can be no assurance that the statement, expectation, or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, actions by regulatory agencies, and those other factors detailed in the company's filings to the CDAR and the SEC. OnClinic does not undertake any obligation to update these forward-looking statements except as required by applicable laws. Joining me this morning to discuss our recent accomplishments, in addition to what we're looking forward to in 2025, Chairman of OnClinic's Board of Directors and Interim CEO, Wayne Pisano, Chief Medical Officer, Dr. Tom Heinemann, Chief Financial Officer, Kirk Look, and Vice President of Business Development, Christophe Deglois. get us started, I'd like to hand it to Wayne, who will provide us with an introduction and overview.

Wayne?